Antihypertensive activity of an alkyl ether analog of phosphatidylcholine

doi:10.1016/0006-291X(79)91163-X

Biochemical and Biophysical Research Communications

Volume 90, Issue 4, 29 October 1979, Pages 1194-1200

https://doi.org/10.1016/0006-291X(79)91163-X Get rights and content

Summary

An alkyl ether analog of phosphatidylcholine was prepared from choline plasmalogen of fresh beef heart by reducing the alk-1-enyl moiety to an alkyl group and by hydrolyzing the sn-2 acyl moiety and replacing it with an acetoyl group. The basis for preparing and testing this compound resulted from experience with antihypertensive lipids derived from the renal medulla and from experience with ether lipid biochemistry. The alkyl lipid analog was found to possess powerful antihypertensive properties in the one-kidney, one-clip hypertensive rats when given either intravenously or orally. This activity induced acute and prolonged depressor effects. These actions were similar to those of a glycerophosphate obtained from fresh renal medulla and designated as APRL (antihypertensive polar renomedullary lipid).

References (21)

BlankM.L. et al.
Biochim. Biophys. Acta
(1973)
SnyderF. et al.
J. Biol. Chem.
(1971)
ChapmanD. et al.
J. Biol. Chem.
(1966)
MuirheadE.E. et al.
Am J. Pathol.
(1958)
MuirheadE.E.
Adv. Int. Med.
(1974)
MuirheadE.E. et al.
Kidney Int.
(1975)
MuirheadE.E. et al.
MuirheadE.E. et al.
J. Lab. Clin. Med.
(1966)
MuirheadE.E. et al.
Lab. Invest.
(1977)
PrewittR.L. et al.
Hypertension
(1979)

There are more references available in the full text version of this article.

Cited by (442)

Signal terminator or signal initiator? The inscrutable role of lipoprotein-associated PAF-acetylhydrolase (PAF-AH) in inflammation
2023, Phospholipases in Physiology and Pathology: Volumes 1-7
Platelet-activating factor acetylhydrolases (PAF-AHs) are a group of Ca2+-independent phospholipase A2s, capable of hydrolyzing the platelet activating factor (PAF)—the most potent phospholipid mediators of inflammation. Distributed both in plasma and in intracellular compartments, PAF-AHs exist in multimolecular forms. 4% of the Japanese exhibit a single point mutation in plasma form of PAF-AH that makes PAF-AH functionally inactive, rendering these subjects more susceptible to a range of inflammatory conditions. Besides PAF, some of the isoforms can also recognize sn-2 modified phospholipids (arising due to oxidation) as their substrates. Despite their ability to hydrolyze PAF, a correlation between the severity of cardiovascular diseases with the increase in plasma PAF-AH levels has raised concerns regarding beneficial role of PAF-AH. This chapter provides an overview of PAF-AHs in general and also seeks to discuss the ambiguous nature of PAF-AH.
Effect of acyl and alkyl analogs of platelet-activating factor on inflammatory signaling
2020, Prostaglandins and Other Lipid Mediators
Citation Excerpt :
Platelet-activating factor (PAF), a simple ether phospholipid [1–4], is chemically identified as 1-O-alkyl/alkenyl-2-acetyl-sn-glycero-3-phosphocholine (Fig. 1) [1–7].
Platelet-activating factor (PAF), a bioactive ether phospholipid with significant pro-inflammatory properties, was identified almost half a century ago. Despite extensive study of this autocoid, therapeutic strategies for targeting its signaling components have not been successful, including the recent clinical trials with darapladib, a drug that targets plasma PAF-acetylhydrolase (PAF-AH). We recently provided experimental evidence that the previously unrecognized acyl analog of PAF, which is concomitantly produced along with PAF during biosynthesis, dampens PAF signaling by acting both as a sacrificial substrate for PAF-AH and probably as an endogenous PAF-receptor antagonist/partial agonist. If this is the scenario in vivo, PAF-AH needs to catalyze the selective hydrolysis of alkyl-PAF and not acyl-PAF. Accordingly, different approaches are needed for treating inflammatory diseases in which PAF signaling is implicated. The interplay between acyl-PAF, alkyl-PAF, PAF-AH, and PAF-R is complex, and the outcome of this interplay has not been previously appreciated. In this review, we discuss this interaction based on our recent findings. It is very likely that the relative abundance of acyl and alkyl-PAF and their interactions with PAF-R in the presence of their hydrolyzing enzyme PAF-AH may exert a modulatory effect on PAF signaling during inflammation.
Forty five years with membrane phospholipids, phospholipases and lipid mediators: A historical perspective
2016, Biochimie
Citation Excerpt :
However, on October 10, 1979, Donald Hanahan, from San Antonio (TX), reported that 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (presented under the name of acetyl glyceryl ether phosphorylcholine or AcGEPC) displayed exactly the properties of PAF [127]. Nineteen days later, Fred Snyder, from Oak Ridge (TN), reported the same structure for Antihypertensive Polar Renomedullary Lipid (APRL) [128]. The game was almost over and Jacques Benveniste had lost the battle of the PAF structure, despite a short publication in French submitted on November 19, 1979 and promoting the name of PAF-acether [129].
Phospholipases play a key role in the metabolism of phospholipids and in cell signaling. They are also a very useful tool to explore phospholipid structure and metabolism as well as membrane organization. They are at the center of this review, covering a period starting in 1971 and focused on a number of subjects in which my colleagues and I have been involved. Those include determination of phospholipid asymmetry in the blood platelet membrane, biosynthesis of lysophosphatidic acid, biochemistry of platelet-activating factor, first attempts to define the role of phosphoinositides in cell signaling, and identification of novel digestive (phospho)lipases such as pancreatic lipase-related protein 2 (PLRP2) or phospholipase B. Besides recalling some of our contributions to those various fields, this review makes an appraisal of the impressive and often unexpected evolution of those various aspects of membrane phospholipids and lipid mediators. It is also the occasion to propose some new working hypotheses.
Acyltransferases and transacylases that determine the fatty acid composition of glycerolipids and the metabolism of bioactive lipid mediators in mammalian cells and model organisms
2014, Progress in Lipid Research
Citation Excerpt :
PAF was first described as a factor released from IgE-stimulated basophils that could trigger the aggregation of rabbit platelets [410]. Its chemical structure was elucidated in 1979 as 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine [410–413]. PAF is a biologically active glycerophospholipid that is now assumed to act as a chemical mediator of anaphylaxis, septic shock, and various inflammatory reactions.
Over one hundred different phospholipid molecular species are known to be present in mammalian cells and tissues. Fatty acid remodeling systems for phospholipids including acyl-CoA:lysophospholipid acyltransferases, CoA-dependent and CoA-independent transacylation systems, are involved in the biosynthesis of these molecular species. Acyl-CoA:lysophospholipid acyltransferase system is involved in the synthesis of phospholipid molecular species containing sn-1 saturated and sn-2 unsaturated fatty acids. The CoA-dependent transacylation system catalyzes the transfer of fatty acids esterified in phospholipids to lysophospholipids in the presence of CoA without the generation of free fatty acids. The CoA-dependent transacylation reaction in the rat liver exhibits strict fatty acid specificity, i.e., three types of fatty acids (20:4, 18:2 and 18:0) are transferred. On the other hand, CoA-independent transacylase catalyzes the transfer of C20 and C22 polyunsaturated fatty acids from diacyl phospholipids to various lysophospholipids, especially ether-containing lysophospholipids, in the absence of any cofactors. CoA-independent transacylase is assumed to be involved in the accumulation of PUFA in ether-containing phospholipids. These enzymes are involved in not only the remodeling of fatty acids, but also the synthesis and degradation of some bioactive lipids and their precursors. In this review, recent progresses in acyltransferase research including the identification of the enzyme’s genes are described.
Platelet-Activating Factor
2007, Methods in Enzymology
Citation Excerpt :
Platelet-activating factor (PAF) is a local mediator with proinflammatory, vasoactive, thrombotic, and other paracrine and autocrine actions. PAF has the chemical structure 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (1-O-alkyl-2-acetyl-GPC) (Benveniste et al., 1979; Blank et al., 1979; Demopoulos et al., 1979; Hanahan et al., 1980). The alkyl moiety is composed almost entirely of hexadecyl (16:0), octadecyl (18:0), and octadecenyl (18:1) chains, although other alkyl chains also exist (Mueller et al., 1984).
Platelet-activating factor (PAF) is a potent mediator that occurs at very low concentrations in cells and tissues. Accurate quantitation of PAF has always been difficult because of the physicochemical properties of PAF and its structural similarity to several much more abundant phospholipids. Numerous assays for PAF have been developed, all of which have their strengths and limitations. Herein, this chapter describes a high-pressure liquid chromatography (HPLC)–tandem mass spectrometry assay for PAF. Major strengths of the method are its sensitivity (detection limit = 1 pg) and selectivity. Another advantage is that, by using liquid instead of gas chromatography, sample derivatization is avoided. The limitations of the method are its use of expensive instrumentation and the requirement of performing two HPLC runs per sample. Detailed technical advice on application of the method to various types of samples is given.
Attenuation of folic acid-induced renal inflammatory injury in platelet-activating factor receptor-deficient mice
2006, American Journal of Pathology
Platelet-activating factor (PAF), a potent lipid mediator with various biological activities, plays an important role in inflammation by recruiting leukocytes. In this study we used platelet-activating factor receptor (PAFR)-deficient mice to elucidate the role of PAF in inflammatory renal injury induced by folic acid administration. PAFR-deficient mice showed significant amelioration of renal dysfunction and pathological findings such as acute tubular damage with neutrophil infiltration, lipid peroxidation observed with antibody to 4-hydroxy-2-hexenal (day 2), and interstitial fibrosis with macrophage infiltration associated with expression of monocyte chemoattractant protein-1 and tumor necrosis factor-α in the kidney (day 14). Acute tubular damage was attenuated by neutrophil depletion using a monoclonal antibody (RB6-8C5), demonstrating the contribution of neutrophils to acute phase injury. Macrophage infiltration was also decreased when treatment with a PAF antagonist (WEB2086) was started after acute phase. In vitro chemotaxis assay using a Boyden chamber demonstrated that PAF exhibits a strong chemotactic activity for macrophages. These results indicate that PAF is involved in pathogenesis of folic acid-induced renal injury by activating neutrophils in acute phase and macrophages in chronic interstitial fibrosis. Inhibiting the PAF pathway might be therapeutic to kidney injury from inflammatory cells.

View all citing articles on Scopus

View full text

Antihypertensive activity of an alkyl ether analog of phosphatidylcholine

Summary

Biochim. Biophys. Acta

J. Biol. Chem.

J. Biol. Chem.

Am J. Pathol.

Adv. Int. Med.

Kidney Int.

J. Lab. Clin. Med.

Lab. Invest.

Hypertension